Veradermics, Incorporated (MANE)

NYSE: MANE · USD

$142

+1.28 (+0.9%)· Recorded snapshot

Market cap	5.9B
Net income (ttm)	-104.3M
EPS (ttm)	-$6.44
Shares out	41.8M
Volume	353,678

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -104.3M
EPS (ttm): -$6.44
Market cap: 5.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ホールド

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROICn/a

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All MANE indicators

Market & fundamental data

Available fields

152

Groups with data

Currency

USD

Showing 152 of 152 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001827635
Company name	Veradermics, Incorporated
Country	United States
Country code	US
CUSIP number	922967104
Earnings date	2026-11-10
Earnings time	amc
Employees	37
Enterprise value	$5.1B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2019
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2026-02-04
Is primary listing	Yes
Is SPAC	No
ISIN number	US9229671048
Last 10-K release date	2026-03-30
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$5.9B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$142.00
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	MANE
Tags	pharmaceuticals
U.S. state	Connecticut
Website	https://www.veradermics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-4.54%
FCF / EV yield	-1.57%
FCF yield	-1.34%
P/B ratio	7.23x
Price / tangible book value	7.16x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.8M
ROCE	-12.63%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-26,000
EBIT	$-102.8M
EPS	$-6.44
FCF per share	$-1.87
Financing cash flow	$862.4M
Free cash flow	$-78.3M
Free cash flow minus SBC	$-88.2M
Investing cash flow	$-473.4M
Net cash flow	$310.7M
Net income	$-104.3M
Operating cash flow minus SBC	$-88.2M
Operating income	$-102.8M
Stock-based compensation	$9.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$19.47
Debt / equity	0
Long-term assets	$989,000
Long-term liabilities	$428,000
Net cash (debt)	$819.5M
Net cash / market cap	14.07%
Net cash growth	1,443.72%
Net debt / equity	-1.01
Piotroski F-Score	2
Property, plant and equipment	$989,000
Shareholders' equity	$813.6M
Tangible book value	$813.6M
Tangible book value per share	$19.47
Total assets	$825.7M
Total cash	$819.9M
Total debt	$428,000
Total liabilities	$12.1M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$824.7M
Current liabilities	$11.7M
Current ratio	70.53
Net working capital	$-6.8M
Quick ratio	70.25
Working capital	$813.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2,096.15%
Dividend yield	0%
Shareholder yield	-2,096.15%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$103.68
1D price change	0.91%
1M price change	21.38%
1M total return	21.38%
1W price change	11.31%
1W total return	11.31%
20-day SMA	$124.46
3M price change	26.99%
3M total return	26.99%
50-day SMA	$113.19
52-week high	$142.89
52-week high date	2026-10-28
52-week low	$32.00
52-week low date	2026-02-04
6M price change	41.35%
6M total return	41.35%
All-time high	$142.89
All-time high date	2026-10-28
All-time low	$32.00
All-time low date	2026-02-04
Average true range (ATR)	$7.86
Average volume	833.6K
Beta (1Y)	0.28
Change from 52-week high	-0.62%
Change from 52-week low	343.75%
Change from all-time high	-0.12%
Change from all-time low	342.16%
Change from open	2.53%
Day's gap	-1.58%
Dollar volume	$50.2M
High price	$142.00
Low price	$138.10
Monthly RSI	0
Open price	$138.50
Position in 52-week range	100%
Premarket change	0.03%
Premarket close	$140.72
Premarket price	$140.76
Premarket volume	1.3K
Previous close	$140.72
Price vs 150-day SMA	36.47%
Price vs 20-day SMA	13.68%
Price vs 50-day SMA	25%
Relative volume	0.42
Return from IPO open	309.97%
Return from IPO price	719.94%
RSI	66.56
Sharpe ratio	2.35
Sortino ratio	4.83
Volume	353.7K
Weekly RSI	67.88

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32.3M
Float percentage	77.29%
Shares change (QoQ)	78.1%
Shares change (YoY)	2,096.15%
Shares held by insiders	2.67%
Shares held by institutions	75.85%
Shares outstanding	41.8M
Short % of float	13.14%
Short % of shares	10.16%
Short ratio	5.8 days

Deeper analysis on MANE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this MANE report

Is a complete MANE research report available?

No complete published report is available for Veradermics, Incorporated (MANE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Veradermics, Incorporated (MANE)

Price

Financial snapshot

Fair-value bridge

Latest news · MANE

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All MANE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on MANE

Frequently asked questions